VOR and REGMY Related Headlines
Go Back- Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
- Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
- Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
- Vor Bio reports positive telitacicept trial results in kidney disease
- Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
VOR and REGMY Related Press Releases
Go Back- Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis
- Telitacicept Receives NMPA Approval for the Treatment of Sjögren’s Disease in China
- Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China
- Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine
